RES 529

Drug Profile

RES 529

Alternative Names: P 529; P 52901; Palomid 529; Palomids; RES-529; SG-00529

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Paloma Pharmaceuticals
  • Developer Diffusion Pharmaceuticals; National Cancer Institute (USA)
  • Class Antiepileptic drugs; Antifibrotics; Antineoplastics; Antipsoriatics; Chromans; Eye disorder therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis stimulants; Hypoxia-inducible factor 1 inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors; Proto oncogene protein c-akt inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Age-related macular degeneration
  • Preclinical Atopic dermatitis; Breast cancer; Cancer; Diabetic retinopathy; Epilepsy; Glioblastoma; Proliferative vitreoretinopathy; Prostate cancer; Psoriasis; Scars
  • Research Pulmonary fibrosis; Rosacea

Most Recent Events

  • 15 Apr 2016 Phase-I development is ongoing for Age-related macular degeneration in USA
  • 15 Mar 2016 Preclinical trials in Breast cancer in USA (PO)
  • 15 Mar 2016 Preclinical trials in Glioblastoma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top